Literature DB >> 12469329

Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein.

Lisa L von Moltke1, James L Weemhoff, Michael D Perloff, Leah M Hesse, Jerold S Harmatz, Barbara F Roth-Schechter, David J Greenblatt.   

Abstract

The influence of high concentrations of zolpidem (100 microM, corresponding to approximately 200 times maximum therapeutic concentrations) on the activity of six human Cytochrome P450 (CYP) enzymes was evaluated in a model system using human liver microsomes. Zolpidem produced negligible or weak inhibition of human CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A. Transport of rhodamine 123, presumed to be mediated mainly by the energy-dependent efflux transport protein P-glycoprotein, was studied in a cell culture system using a human intestinal cell line. High concentrations of zolpidem (100 microM), exceeding the usual therapeutic range by more than 100-fold, produced only modest impairment of rhodamine 123 transport. The findings indicate that zolpidem is very unlikely to cause clinical drug interactions attributable to impairment of CYP activity or P-gp mediated transport. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12469329     DOI: 10.1002/bdd.329

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  9 in total

1.  Grapefruit juice, lyophilized grapefruit juice, and powdered whole grapefruit inhibit cytochrome P450-mediated triazolam hydroxylation by beagle dog liver microsomes.

Authors:  M J Hanley; R Cerundolo; N Radwanski; M H Court
Journal:  J Vet Pharmacol Ther       Date:  2010-04       Impact factor: 1.786

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

4.  In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

Authors:  Thomas M Polasek; Janani S Sadagopal; David J Elliot; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12-11       Impact factor: 2.953

5.  Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.

Authors:  Joel O Olubodun; Hermann R Ochs; Lisa L von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

6.  Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor.

Authors:  Laurie P Volak; Senait Ghirmai; John R Cashman; Michael H Court
Journal:  Drug Metab Dispos       Date:  2008-05-14       Impact factor: 3.922

Review 7.  Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.

Authors:  Sumit Jain; Vijay Rathod; Rameshwar Prajapati; Prajwal P Nandekar; Abhay T Sangamwar
Journal:  Mol Divers       Date:  2014-09-12       Impact factor: 2.943

8.  Zolpidem : Forensic aspects for the toxicologist and pathologist.

Authors:  Timothy P Rohrig; Christine M Moore
Journal:  Forensic Sci Med Pathol       Date:  2005-06       Impact factor: 2.456

9.  Risk of falling and hypnotic drugs: retrospective study of inpatients.

Authors:  Kyoko Obayashi; Takuya Araki; Katsunori Nakamura; Masahiko Kurabayashi; Yoshihisa Nojima; Katsuyuki Hara; Tomonori Nakamura; Koujirou Yamamoto
Journal:  Drugs R D       Date:  2013-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.